HAYWARD, Calif.--Lynx Therapeutics was recently issued a patent broadly covering its use of encoded adaptors in its Massively Parallel Signature Sequencing technology. The company has also acquired an exclusive worldwide license to a molecular tagging technology invented by George Church and Stephen Kieffer-Higgins at Harvard Medical School.
Norrie Russell, Lynx’s CEO, said the company’s intellectual property portfolio now includes 49 patents in the area of genomics, DNA analysis, and DNA chemistry. Said Russell, "Encoded adaptors are a key element of our MPSS technology since they increase the efficiently of the method by almost an order of magnitude." He added that the license to the Harvard technology broadens the reach of Lynx’s existing patents covering its Megaclone technology, which enables simultaneous manipulation and analysis of very complex mixtures of millions of DNA molecules or fragments.